Kinetics of lymphokine production in HIV+ patients treated with highly active antiretroviral therapy and interleukin 2

Journal of Clinical Immunology

Volumn 19, Issue 5, 1999, Pages 317-325

  De Paoli, Paolo ^a   Zanussi, Stefania ^a   Caggiari, Laura ^a   Bortolin, Maria Teresa ^a   D'Andrea, Monica ^a   Simonelli, Cecilia ^a   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Highly active antiretroviral therapy; HIV infection; IL 16; IL 2 production; IL 2 therapy

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; INDINAVIR; INTERLEUKIN 16; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; LYMPHOKINE; RECOMBINANT INTERLEUKIN 2; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; GASTROINTESTINAL SYMPTOM; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; IN VITRO STUDY; MALE; MONONUCLEAR CELL; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; VIREMIA;

ADULT; ANTI-HIV AGENTS; ANTIGENS, CD; ANTIGENS, CD24; CD4-CD8 RATIO; CYTOKINES; FEMALE; FLOW CYTOMETRY; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HUMANS; INDINAVIR; INTERLEUKIN-16; INTERLEUKIN-2; LYMPHOKINES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PHYTOHEMAGGLUTININS; RECEPTORS, INTERLEUKIN-2; REVERSE TRANSCRIPTASE INHIBITORS; T-LYMPHOCYTE SUBSETS; UP-REGULATION;

EID: 0032882119     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020547826191     Document Type: Article

References (37)

1. 1. Schwartz DH, Skowron G, Merigan TC: Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J Acquir Immune Defic Syndr 4:11-23, 1991
2. 2. Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey RT, Faloon J, Polis MA, Walker RE, Stevens R, Salzman NP, Metcalf JA, Masur H, Lane HC: Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med 332:567-575, 1995
3. 3. Leef Jacobson E, Pilaro F, Smith KA: Rational interleukin 2 therapy for HIV positive individuals: Daily low doses enhance immune function without toxicity. Proc Natl Acad Sci USA 93:1045-10410, 1996
4. 4. Teppler H, Kaplan G, Smith KA, Montana AL, Mcyn P, Cohn ZA: Prolonged immunostimulatory effect of low-dose polyethylene glicol interleukin 2 in patients with human immunodeficiency virus type 1 infection. J Exp Med 177:483-492, 1993
5. 5. Scadden DT: Cytokine use in the management of HIV diseuse. J. Acquir Immune Defic Syndr Human Retrovir 16:S23-S29, 1997
6. 6. Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT, Walker RE, Polis MA, Spooner K, Metcalf JA, Baseler M, Fyfe G, Lane HC: Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 335:1350-1356, 1996
7. 7. Davey RD, Chaitt DG, Piscitelli SC, Wells M, Kovacs J, Walker RE, Falloon J, Polis MA, Metcalf JA, Masur H, Fyfe G, Lane HC: Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected person. J Infect Dis 175:781-789, 1997
8. 8. Levy Y, Capitant C, Houhou S, Carriere I, Gaustault JA, Viard JP, Aboulker JP: IL2 in HIV patients: A randomized trial comparing SC, PEG, CIV IL2 with AZT + ddi. In 12th International Conference on AIDS, Geneva 1998, abstr 41229
9. 9. Piscitelli SC, Wells MJ, Metcalf JA, Baseler M, Stevens R, Davey R: Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIV-infected patients, Pharmacotherapy 16:754-759, 1996
10. 10. De Paoli P, Zunussi S, Simonelli C, Bortolin MT, D'Andrea M, Crepaldi C, Talamini R, Comar M, Giacca M, Tirelli U: Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects. J Clin Invest 100:2737-2743, 1997
11. 11. Connors M, Kovacs JA, Kreval S, Gea-Banacloche J, Sneller MC, Flanigan M, Metcalf J, Walker RE, Falloun J, Baseler M, Stevens R, Feuerstein I, Masur H, Lane HC: HIV infection induces changes in CD4+ T cell phenotype and depletion within the CD4 T cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 3:533-540, 1997
12. 12. Van Lunzen J, Tenner-Racs K, Racz P, Hufert FI, Lauer J, Stellbrink HJ: Effect of HAART ± IL-2 on viral kinetics and T cell reconstitution in lymphoid tissues of asymptomatic HIV-infected patients. In 12th International Conference on AIDS, Geneva 1998, abstr 41228
13. 13. Woods TC, Roberts BD, Butera ST, Folks TM: Loss of inducible virus in CD45RA naive cells after HIV-1 entry accounts for preferential viral replication in CD45R0 memory cells. Blood 89:1635-1641, 1997
14. 14. Zanussi S, Simonelli C, Bortolin MT, D'Andrea M, Crepaldi C, Vaccher E, Nasti G, Politi D, Barzan L, Tirelli U, De Paoli P: Immunological changes in peripheral blood and lymphoid tissue after treatment of HIV-infected subjects with HAART or HAART + IL-2. Clin Exp Immunol 116:486-492, 1999
15. 15. Simonelli C, Zanussi S, Sandri S, Comar M, Lucenti A, Talamini R. Bortolin MT, Giacca M, De Paoli P, Tirelli U; Concomitant therapy with s.c. IL-2 and AZT plus ddI in patients with early stage HIV infection. J Acquir Immune Defic Syndr Human Retrovir 20:20-27, 1999
16. 16. Hanninen EL, Korfer A, Hadam M, Schneekloth K, Dalmann I, Menzel T, Kirchner H, Poliwoda H, Atzpodien J: Biological monitoring of low dose IL-2 in humans: sIL2R, cytokines and cell surface phenotypes. Cancer Res 50:6312-6316, 1991
17. 17. Kinter A, Bende S, Hardy E, Jackson R, Fauci AS: IL-2 induces CD8+ T cell mediated suppression of HIV replication in CD4+ T cells and this effect overrides its ability to stimulate virus expression. Proc Natl Acad Sci USA 92:10985-10989, 1995
18. 18. Baier M, Wermer A, Bannert N, Metzner K, Kurth R: HIV suppresion by Interleukin-16. Nature 378:563, 1995
19. 19. Center DM, Kornfield H, Cruikshank W: IL-16 and its function as a CD4 ligand, Immunol Today 17:476-481, 1996
20. 20. Baier M, Kurth R: Fighting HIV-1 with IL-16. Nat Med 3:605-606, 1997
21. 21. Zhou P, Goldstein S, Devadas K, Tewari D, Notkins A: Human CD4+ cells transfected with IL-16 cDNA are resistant to HIV-1 infection:inhibition of mRNA expression. Nat Med 3:659-664, 1997
22. 22. Centre for Disease Control: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescent and adults. MMWR 41:1-19, 1992
23. 23. Zanussi S, Simonelli C, Bortolin MT, D'Andrea M, Comar M, Tirelli U, Giacca M. De Paoli P: Dynamics of provirus load and lymphocyte subsets after IL-2 treatment in HIV-infected patients. AIDS Res Hum Retrovir 15:97-103, 1999
24. 24. Zamissi S, D'Andrea M, Simonelli C, Tirelli U, De Paoli P: Serum levels of RANTES and MIP-1 in HIV-positive long term survivors and progressor patients. AIDS 10:1450-1451, 1996
25. 25. Jung T, Schauer U, Heusser C, Neumann C, Rieger C: Detection of intracellular cytokines by flow cytometry. J Immunol Methods 159:197-207, 1993
26. 26. Klein S, Dobmeyer J, Dobmeyer T, Pape M, Ottman O, Helm E, Hoelzer D, Rossol R: Demonstration of the Th1 to Th2 cytokine shift during the course of HIV 1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS 11:1111-1118, 1997
27. 27. Morgan DA, Ruscetti FW, Gallo R: Selective in vitro growth of lymphocytes from normal human bone marrows. Science 193: 1007-1008, 1976
28. 28. Deehan DJ, Heys SD, Simpson WG, Broom J, Franks C, Eremin O: In vivo cytokine production and recombinant IL-2 immunotherapy: An insight into the possible mechanisms underlying clinical response. Br J Cancer 69:1130-1135, 1994
29. 29. Gorochcov G, Neumann A, Kereveur A, Parizot C, Li T, Katlama C, Karmochkine M, Raguin G, Autran B, Debre P: Perturbation of CD4 + and CD8 + T-cell repertoires during progression to AIDS and regulation of the CD4 + repertoire during antiviral therapy. Nat Med 4:215-221, 1998
30. 30. Fleury S, deBoer R, Rizzardi GP, Wolthers K, Otto S, Welbon C, Graziosi C, Knabenhans C, Soudeyns H, Bart P, Gallant S, Corpataux J, Gillet M, Meylan P, Schnyder P, Meuwly J, Spreen W, Glauser M, Miedema F, Pantaleo G: Limited CD4 + T-cell renewal in early HIV infection: Effect of highly active antiretroviral therapy. Nat Med 4:794-801, 1998
31. 31. Autran B, Carcelain G, Li T, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, Leibovitch J: Positive effects of combined antiretroviral therapy on CD4 + T cell homeostasis and function in advanced HIV disease. Science 277:112-116, 1997
32. 32. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B: Long-lasting recovery in CD4 T-cell function and viral-load reduction after HAART in advanced HIV-1 disease. Lancet 351: 1682-1686, 1998
33. 33. Nielsen SD, Afzelius P, Dam-Larsen S, Nielsen C, Nielsen JO, Mathiesen L, Hansen JF: Effect of G-CSF in HIV-infected patients: Increase in numbers of naive CD4 and CD34 cells makes G-CSF a candidate for use in gene therapy or to support antiretroviral therapy. J Infect Dis 177: 1733-1736, 1998
34. 34. Zou W, Foussat A, Houliou S, Durand-Gasselin I, Dulioust A, Bouchet L, Galanaud P, Levy Y, Emilie D, for the ANRS 048 IL-2 study: Acute up-regulation of CCR-5 expression by CD4+ T lymphocytes in HIV-infected patients treated with IL-2. AIDS 13:455-463, 1999
35. 36. Smith K, Cantrell DA: IL-2 regulates its own receptors, Proc. Natl Acad Sci USA 82:864-868, 1995
36. 37. Kradin R, Kurnick J, Gifford J, Pinto C, Preffer F, Lazurus D: Adoptive immunotherapy with IL-2 results in disminished IL-2 production by stimulated peripheral blood lymphocytes. J Clin Immunol 9:378-385, 1989
37. 38. Levacher M, Hulstaert F, Tallet S, Ullery S, Pocidalo JJ, Bach BA: The significance of activation markers on CDS lymphocytes in HIV syndrome: Staging and prognostic value. Clin Exp Immunol 90:376-382, 1992